Mission
Develop therapeutics that ablate cancer stem cells
About Escend Pharmaceuticals
Escend is a privately held clinical-stage company. Our business model is to reduce drug development risk by screening, selecting, and developing foreign-approved drugs with known clinical safety for orphan cancer indications based on new mechanisms of action. Our unique compound screening processes help accelerate drug discovery and development time by utilizing parallel and integrative biological and medicinal chemistry approaches.
Escend creates new intellectual property centered around methods of use and composition claims to focus on new mechanisms of action details. We identify and match drug candidates with high clinical unmet disease indications to reduce clinical and regulatory approval risks.
The Escend Team
The Escend founders have collective experience in cancer research, drug discovery, drug delivery technologies, and clinical drug development. In addition, our skills involve developing and implementing intellectual property strategies around compositions of matter and method of use claims. With our strong foundation, we utilize several approaches to identify small molecules with previous pre-clinical and clinical experience that can be utilized for accelerated development as novel therapeutics.
Team
Saira Bates, MBA
Co-Founder & CEO
Neil Sankar, MD
Medical Director & Safety Monitoring
Mark Jaros, PhD
Data Management & Statistics
Sarath Kanekal
DVM, PhD, DABT, RA
Pharmacology, Toxicology & Regulatory
Diann Nagami, PhD
CMC & Regulatory
Dennis Brown, PhD
Co-Founder & Chairman
Mike Li, MS
Chemistry, Manufacturing & Controls (CMC)
Advisors
Jorge Cortes, MD
Professor, Director, Georgia Cancer Center, Augusta University
Susan O’Brien, MD
Professor, Division of Hematology/Oncology, University of California, Irvine
Shaoguang Li, MD, PhD
Professor, Department of Medicine, UMass Chan Medical School